Pioneering ASD Therapy Trials by SciSparc
SciSparc embarks on groundbreaking clinical trials for SCI-210, aiming to revolutionize autism spectrum disorder therapy with its novel cannabinoid-based formulation.
NAVIGATING THE FUTURE OF AUTISM THERAPEUTICS: FROM CURRENT TREATMENTS TO INNOVATIVE DRUG DISCOVERY
Pharmacological Therapies for Autism Spectrum Disorder: A Comprehensive Review
This review delves into the current state and future prospects of pharmacological treatments for ASD, highlighting risperidone and aripiprazole as mainstays while exploring emerging therapies.
Medications for Autism's Core Symptoms
Autism Speaks provides insights into the medications beneficial for easing core symptoms of autism, with a focus on risperidone and aripiprazole, and the potential for new medicines on the horizon.
Medication Treatment for Autism: NICHD's Perspective
NICHD outlines the use of antipsychotic drugs like risperidone and aripiprazole for treating irritability associated with ASD, emphasizing the importance of behavioral therapies in conjunction with medication.
Autism Spectrum Disorder Therapeutics Market Forecast
DelveInsight's report on the ASD therapeutics market projects substantial growth, driven by a robust pipeline of potential therapies and strategic collaborations within the pharmaceutical industry.
Autism and Medication: Child Mind Institute's Insights
Exploring the nuanced role of medication in managing autism symptoms, the Child Mind Institute discusses the FDA-approved antipsychotics Abilify and Risperdal, and the broader spectrum of symptom-targeted medications.
Challenges and Future Directions in ASD Drug Development
This article addresses the hurdles in ASD drug development, including heterogeneity and the lack of validated biomarkers, while offering insights into promising research strategies for therapeutic advancements.